Trial Profile
A Phase 1, Fixed-Sequence, Open-Label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor), Cigarette Smoking (CYP1A2 Inducer) and Itraconazole (CYP3A4 Inhibitor) on the Pharmacokinetics of TD-9855 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ampreloxetine (Primary) ; Caffeine; Fluvoxamine; Itraconazole
- Indications Orthostatic hypotension
- Focus Pharmacokinetics
- Sponsors Theravance Biopharma
- 18 Jun 2018 Status changed from not yet recruiting to completed.
- 16 Feb 2018 New trial record